Drug Trial Radar · NCT06772870
A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants
Last checked: Nov 20, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Feb 2025
Primary completion
Sep 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Design Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of DT-216P2 administered either subcutaneously (SC) and intravenously (IV) in normal healthy participants. Approximately 36 participants will be enrolled into this study.
Conditions
- Friedreich Ataxia
Interventions
DT-216P2Drug
DT-216P2 will be administered as subcutaneous injection, subcutaneous infusion and intravenous infusion.
SalineDrug
Normal saline solution will be used as placebo control.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of treatment emergent adverse events (TEAEs)Time frame: From first dose to end of study, Day 30 post first dose administration.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network, Level 5, 89 Commercial Road
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.